Antifungal Drugs Market to Grow at a CAGR of 3.2% to reach US$ 13,524.2 Million from 2019 to 2027

Antifungal Drugs Market to 2027 - Global Analysis and Forecasts By Infection Type (Superficial Fungal Infection, Systemic Fungal Infection); Drug Type (Echinocandins, Azoles, Polyenes, Allylamines, Others); Therapeutic Indication (Aspergillosis, Dermatophytosis, Candidiasis, Others); Dosage form (Drugs, Ointment, Powder, Others), and Geography

Publication Month: Jul 2019 | Report Code: TIPRE00003745 | No. of Pages: No. of Pages150 | Category: Pharmaceuticals | Status: Published

The Antifungal Drugs market accounted to US$ 10,182.3 Mn in 2018 and is expected to grow at a CAGR of 3.2% during the forecast period 2019 – 2027, to account to US$ 13,524.2 Mn by 2027.

Asia Pacific is the fastest growing geographic market and it is expected to be the fastest revenue contributor throughout the forecast period. Asia Pacific is recognized as a developing market for the pharmaceutical. The growth is driven by that countries such as China, and India which are engaged in conducting several studies.

 Lucrative Regional Antifungal Drugs Markets

Get more information on this report :


Market Insights

Increasing Incidence of Cancers, HIV, and Hospital-Acquired Infections

The incidence of fungal infections due to numerous diseases has increased over the last few decades. Furthermore, bloodstream infection incidence is bimodal, with adult people and premature babies having the maximum risk. Cancer treatment using chemotherapy and radiation causes various changes in the body as they destruct cancer cells. Among the significant difference, one is that this treatment weakens the immune system that increases the chances of getting a fungal infection.

Many fungal infections are called opportunistic infections, as they generally affect people with weak immune systems. As HIV weakens the immune system, it is more prone to have some types of fungal infections, like coccidioidomycosis, histoplasmosis, cryptococcosis, and pneumocystis pneumonia (PCP).

According to data published by J. Fungi 2017, approximately 3,000,000 cases of chronic pulmonary aspergillosis, around 223,100 cases of cryptococcal meningitis among HIV/AIDs patients. And nearly 700,000 cases of invasive candidiasis, about 250,000 cases of invasive aspergillosis, approximately 100,000 cases of disseminated histoplasmosis, more than 10,000,000 cases of fungal asthma, and around 1,000,000 cases of fungal keratitis occur per annum.

Growing Pharmaceutical Industry in Developing Regions

The developing nations are incredibly diverse, and the diseases and health care problems they face are somewhat variable. Thus, the solutions are different and must be made to fit local circumstances. Emerging nations represent an excellent opportunity for the pharmaceutical industry. The emerging markets are expected to be the crucial factor for offering better and lucrative growth opportunities for the market players to expand their business and geographic reach.

The treatment for the fungal infections become more straightforward due to the help of the advancement in the technologies. Also, the healthcare expenditure has created lots of opportunities for the developing nations to provide better and more services and facilities to their people. Regions like Asia, the Middle East, and Africa are investing more in the healthcare sectors.

According to World Health Organization (WHO), between 2015 and 2020, the pharma sales growth predictions scored higher in developing countries as compared in developed countries, with BRIC-MT (Mexico and Turkey) countries positioning first with a 9.3% growth in sales.

Several factors contribute to the fast growth of pharma emerging markets. The first factor is the patent cliff touching several registered drugs used in the market for several years. Next is the inclination towards the use of generic drugs in established and emerging countries, and the growing availability of biosimilar drugs. The next factor is the change in disease patterns in developing countries. Finally, the difference between manufacturing costs and charges for pharma growth.

Infection Type Insights

The global Antifungal Drugs market by infection type segments was led by superficial fungal infection. In 2018, the superficial fungal infection segment held a largest market share of 62.1% of the Antifungal Drugs market, by infection type. Also, the superficial fungal infection segment is expected to be the fastest growing segments of the market in 2027 owing to change in the environmental condition across the globe which is expected to become the major factor for the growth of the Antifungal Drugs market.

South and Central America Antifungal Drugs Market, by Infection Type

Get more information on this report :


Strategic Insights

Report CoverageDetails
Market Size Value inUS$ 10,182.3 Million in 2018
Market Size Value byUS$ 13,524.2 Million by 2027
Growth rateCAGR of 3.2% from 2019-2027
Forecast Period2019-2027
Base Year2019
No. of Pages150
No. of Tables95
No. of Charts & Figures70
Historical data availableYes
Segments coveredInfection Type ; Drug Type ; Therapeutic Indication ; Dosage form , and Geography
Regional scopeNorth America; Europe; Asia Pacific; Latin America; MEA
Country scopeUS, UK, Canada, Germany, France, Italy, Australia, Russia, China, Japan, South Korea, Saudi Arabia, Brazil, Argentina
Report coverageRevenue forecast, company ranking, competitive landscape, growth factors, and trends
Free Sample Copy Available

Organic and inorganic growth strategies were observed in global Antifungal Drugs industry. The organic strategies which were conducted more compared to the inorganic strategies for the Antifungal Drugs. For instance, in November, 2017, Merck & Co., Inc. declared that the U.S. Food and Drug Administration (FDA) approved PREVYMIS (letermovir) to be uses as once-daily tablets for oral use and injection for intravenous infusion. Thus, the organic strategy has enabled the company to grow its business in the market.

Antifungal Drugs–MARKET SEGMENTATION

Global Antifungal Drugs Market – By Infection Type

  • Superficial Fungal Infection
  • Systemic Fungal Infection

Global Antifungal Drugs Market – By Drug Type

  • Echinocandins
  • Azoles
  • Polyenes
  • Allylamines
  • Others

Global Antifungal Drugs Market – By Therapeutic Indication

  • Aspergillosis  
  • Dermatophytosis
  • Candidiasis
  • Others

Global Antifungal Drugs Market – By Dosage Form

  • Drugs
  • Ointment
  • Powder
  • Others

By Geography

  • North America

    • U.S.
    • Canada
    • Mexico
  • Europe

    • France
    • Germany
    • UK
    • Spain
    • Italy
  • Asia Pacific (APAC)

    • China
    • India
    • Japan
    • Australia
    • South Korea
  • Middle East & Africa (MEA)

    • Saudi Arabia
    • South Africa
    • UAE
  • South America (SAM)

    • Brazil
    • Argentina

Company Profiles

  • Pfizer Inc.
  • Sanofi S.A.
  • Gilead Sciences, Inc.
  • Merck And Co., Inc.
  • Scynexis Inc.
  • Novartis International AG
  • Abbott Laboratories
  • Bayer AG
  • Glenmark Pharmaceutical
  • Glaxosmithkline Plc.

The List of Companies

  1. Pfizer Inc.
  2. Sanofi S.A.
  3. Gilead Sciences, Inc.
  4. Merck And Co., Inc.
  5. Scynexis Inc.
  6. Novartis International AG
  7. Abbott Laboratories
  8. Bayer AG
  9. Glenmark Pharmaceutical
  10. Glaxosmithkline Plc.
  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Antifungal Drugs market.
  • Highlights key business priorities in order to assist companies to realign their business strategies.
  • The key findings and recommendations highlight crucial progressive industry trends in the global Antifungal Drugs market, thereby allowing players across the value chain to develop effective long-term strategies.
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
  • Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
  • Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.
TIPRE00003745
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Get the Latest COVID-19 Analysis on this market




Have a question?

Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.

Speak To Analyst
Pricing
  • $3000
  • $4550 $3640
  • $6550 $5240
  • $8550 $6840

Sample PDF showcases the content structure and the nature of the information included in the report which presents a qualitative and quantitative analysis.

    Inquire for Discount